Madrigal Pharmaceuticals (MDGL) Net Income Growth (1y) (2011 - 2026)
Madrigal Pharmaceuticals (MDGL) Net Income Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | -0.46% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | -10.08% |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | 63.48% |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 1,228.66% |
| 10 | Madrigal Pharmaceuticals | 16.16 Bn | 15.93 Bn | - | -26.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.03% |
| Dec 31, 2025 | -275.12% |
| Sep 30, 2025 | -3.88% |
| Jun 30, 2025 | 72.21% |
| Mar 31, 2025 | 50.36% |
| Dec 31, 2024 | 59.14% |
| Sep 30, 2024 | -8.33% |
| Jun 30, 2024 | -77.12% |
| Mar 31, 2024 | -91.87% |
| Dec 31, 2023 | -30.60% |
| Sep 30, 2023 | -21.61% |
| Jun 30, 2023 | -21.31% |
| Mar 31, 2023 | -33.69% |
| Dec 31, 2022 | -33.08% |
| Sep 30, 2022 | -28.68% |
| Jun 30, 2022 | -14.73% |
| Mar 31, 2022 | -8.90% |
| Dec 31, 2021 | 66.29% |
| Sep 30, 2021 | -8.83% |
| Jun 30, 2021 | -25.50% |